Research output per year
Research output per year
Personal profile
Biography
Andy Redfern is Associate Professor of Medical Oncology at the University of Western Australia, Associate Director for Clinical Strategy at Harry Perkins Institute of Medical Research, Consultant Medical Oncologist at the Fiona Stanley Hospital, Perth, and Medical Director of Linear Clinical Research specialising in early phase human trials.
Beyond a clinical practice treating breast and urological cancers, Andy is principal investigator for a range of clinical trials across all phases and has a portfolio of translational research initiatives. His research interests centre around growth signalling and mechanisms of chemotherapy and hormone therapy resistance in cancer, differentiation and EMT in cancer progression, tumour-stroma interactions and Indigenous cancer biology.
Andy is also chairman and lead clinician of the State Breast Cancer Collaborative and is on scientific advisory boards for the Cancer Council of Western Australia and the Australasian Breast Cancer Trials Group.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research expertise keywords
- cancer growth signalling
- chemotherapy resistance
- hormone therapy resistance
- cancer progression
- tumour-stroma interactions
Fingerprint
Dive into the research topics where Andrew Redfern is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors
Khan, A., Welman, C. J., Abed, A., O'Hanlon, S., Redfern, A., Azim, S., Lopez, P., Singh, F. & Khattak, A., Mar 2023, In: Cancers. 15, 5, 14 p., 1382.Research output: Contribution to journal › Article › peer-review
Open Access -
Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival
Takano, E. A., Younes, M. M., Meehan, K., Spalding, L., Yan, M., Allan, P., Fox, S. B., Redfern, A., Clouston, D., Giles, G. G., Christie, E. L., Anderson, R. L., Zethoven, M., Phillips, K. A., Gorringe, K. & Britt, K. L., Dec 2023, In: BMC Cancer. 23, 1, 459.Research output: Contribution to journal › Article › peer-review
Open Access -
Stromal inflammation, fibrosis and cancer: An old intuition with promising potential
Oey, O., Sunjaya, A. F., Khan, Y. & Redfern, A., Jul 2023, In: World Journal of Clinical Oncology. 14, 7, p. 230-246Research output: Contribution to journal › Article › peer-review
Open Access -
Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer
Waryah, C., Cursons, J., Foroutan, M., Pflueger, C., Wang, E., Molania, R., Sorolla, A., Wallis, C., Moses, C., Glas, I., Magalhães, L., Thompson, E. W., Fearnley, L. G., Chaffer, C. L., Davis, M., Papenfuss, A. T., Redfern, A., Lister, R., Esteller, M. & Blancafort, P., 4 Aug 2023, In: Advanced Science. 10, 22, 2301802.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus) -
Unpacking the Complexity of Epithelial Plasticity: From Master Regulator Transcription Factors to Non-Coding RNAs
Waryah, C., Alves, E., Mazzieri, R., Dolcetti, R., Thompson, E. W., Redfern, A. & Blancafort, P., Jun 2023, In: Cancers. 15, 12, 3152.Research output: Contribution to journal › Review article › peer-review
Open Access
Datasets
-
Additional file 5 of Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival
Takano, E. A. (Creator), Younes, M. M. (Creator), Meehan, K. (Creator), Spalding, L. (Creator), Yan, M. (Creator), Allan, P. (Creator), Fox, S. B. (Creator), Redfern, A. (Creator), Clouston, D. (Creator), Giles, G. G. (Creator), Christie, E. L. (Creator), Anderson, R. L. (Creator), Zethoven, M. (Creator), Phillips, K. (Creator), Gorringe, K. (Creator) & Britt, K. L. (Creator), Figshare, 19 May 2023
DOI: 10.6084/m9.figshare.22978079.v1, https://springernature.figshare.com/articles/dataset/Additional_file_5_of_Estrogen_receptor_beta_expression_in_triple_negative_breast_cancers_is_not_associated_with_recurrence_or_survival/22978079/1
Dataset
-
Identification and targeting of the oncogene AAMDC in ovarian cancer
Golden, E., Blancafort, P., Cohen, P., Yu, Y., Redfern, A. & Wang, E.
1/01/23 → 30/06/24
Project: Research
-
Zeiss Celldiscoverer7 for automated high resolution imaging of complex biomedical samples
Fox, A., Choi, Y. S., Rodger, J., Tang, A., Hool, L., Pillow, J., Lister, R., Bond, C., Hodgetts, S., Chen, K., Blancafort, P., Redfern, A., Swaminatha Iyer, K., Smith, N., Marshall, A., Fear, M., Wood, F., Evans, C., Chooi, H. & Rassell, A.
National Health & Medical Research Council NHMRC
1/07/22 → 31/10/23
Project: Research
-
TARGETING A NEW SUBTYPE OF ESTROGEN RECEPTOR POSITIVE BREAST CANCER
Blancafort, P., Redfern, A., Golden, E., Johnstone, L., Pavlos, N. & Sharma, A.
National Breast Cancer Foundation
31/05/22 → 31/05/26
Project: Research
-
MRFF RCRDUN - Addressing the poor outcomes of young women with hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer
Redfern, A., Loi, S., Francis, P., Fox, S. & Wilcken, N.
Medical Research Future Fund MRFF
1/01/22 → 31/12/26
Project: Research